RF Acquisition Corp II
corporate_fare Company Profile
RF Acquisition Corp II (NASDAQ:RFAI) is a publicly traded company in the Finance sector. Wiseek has independently scored 12 items for RFAI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-21, rated 8/10. Across its 12 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for RFAI spans 425, 8-K, 10-Q, DEF 14A.
Recent high-impact activity:
- RFAI Stock Explodes 473% After Hours on Nanyang Biologics Merger Approval
- Shareholders Clear Path for RF Acquisition Corp II–Nanyang Biologics Merger
- RF Acquisition Corp II Shareholders Approve Nanyang Biologics Business Combination
- RF Acquisition Corp II Extends SPAC Deadline to February 2027; 833K Shares Redeemed
- RF Acquisition Corp II Extends SPAC Deadline to February 2027 After Shareholder Vote
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 11,647 shares in RFAI as of the September 15, 2026 settlement, a 35.4% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 67.7% of RFAI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
RFAI files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.